PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia
Recruiting · NCT06033131 · Interventional (participants receive a specific treatment) · Lead sponsor: Lina Bergman
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Preterm preeclampsia is a severe condition for both the mother and the fetus. Currently, the only treatment available to stop disease progression is termination/delivery of the fetus and placenta. Therefore, preterm preeclampsia carries the highest rates of neonatal morbidity and mortality due to iatrogenic preterm birth. There is evidence suggesting metformin, a drug commonly used to treat diabetes in and outside pregnancy, may be able to counter the pathophysiology of preeclampsia, raising the possibility that it could be used to treat the condition. This multi centre double blind randomised controlled trial aims to investigate if metformin can prolong gestation, lower neonatal length of stay and increase birthweight in a Nordic setting.
Who can take part
Inclusion criteria
- A diagnosis of preeclampsia (defined as hypertension in combination with significant proteinuria (albumin/creatinine ratio \>8 mg/mmol, protein/creatinine ratio\>30 mg/mmol or \>2+ protein on a urinary dipstick) has been made by the attending clinician
- The managing clinicians have made the assessment to proceed with expectant management.
- The subject has given written consent to participate in the study.
- The woman must be 18 years of age or older
- The gestational age is between 22+0 weeks to 33+6 weeks with a viable fetus
- The woman carries a singleton pregnancy
Exclusion criteria
- Contraindications to treatment with metformin as outlined in SmPC
- Contraindications for expectant management of preeclampsia such as an immediate indication for delivery according to SFOG guidelines for preeclampsia (https://www.sfog.se/media/338533/pe-riktlinje-230214.pdf).
- Type 1 Diabetes Mellitus
- Current use of metformin
- Known or suspected allergies against metformin
- Reluctance or language difficulties that result in difficulty understanding the meaning of study participation
- Unable to understand the informed consent process
- Previous participation in the study
- Established fetal compromise that necessitates imminent delivery (including planned delivery after 48 hours of corticosteroid treatment). This will be decided by the clinical team before expectant management is offered to the patient.
- Suspicion of a major known fetal anomaly or malformation.
- Renal disease or dysfunction, suggested by a creatinine level greater than or equal to 125 µmol/L or rapidly declining renal function
- Known acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Not suitable for inclusion by the opinion of the investigator
Where it is running
17 locations listed.
- Södra Älvsborgs Hospital - Borås, Sweden
- Falu Lasarett - Falun, Sweden
- Sahlgrenska University Hospital - Gothenburg, Sweden
- Helsinki University Hospital - Helsinki, Finland
- Linköping University Hospital - Linköping, Sweden
- Skåne University Hospital - Lund, Sweden
- Akershus University Hospital - Lørenskog, Norway
- Skåne University Hospital - Malmö, Sweden
- Oslo University Hospital - Oslo, Norway
- Karolinska University Hospital Huddinge - Stockholm, Sweden
- Karolinska University Hospital Solna - Stockholm, Sweden
- Danderyd Hospital - Stockholm, Sweden
- Tampere University Hospital - Tampere, Finland
- Norra Älvsborgs County Hospital - Trollhättan, Sweden
- Norrland´s University Hospital - Umeå, Sweden
- Uppsala University Hospital - Uppsala, Sweden
- Västmanlands Hospital Västerås - Västerås, Sweden